Log In
BCIQ
Print this Print this
 

20-2b

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionDock-and-lock (DNL) construct comprised of four interferon-a2b molecules conjugated to veltuzumab, Immunomedics' humanized anti-CD20 antibody
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationLymphoma
Indication DetailsTreat CD20-expressing lymphomas
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today